Evidence map›Paper›PMID 32587390›Full record

ArticleScientific reports2020

Amylin and beta amyloid proteins interact to form amorphous heterocomplexes with enhanced toxicity in neuronal cells.

Prashant Bharadwaj, Tanya Solomon, Bikash R Sahoo, Katarzyna Ignasiak, Scott Gaskin, Joanne Rowles, Giuseppe Verdile, Mark J Howard, Charles S Bond, Ayyalusamy Ramamoorthy and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 69 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. The Aβ42 Peptide and IAPP Physically Interact in a Yeast-Based Assay.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Prashant Bharadwaj *School of Pharmacy and Biomedical Sciences, Curtin Health and Innovation Research Institute (CHIRI), Faculty of Health Sciences, Curtin University, Bentley, WA, 6107, Australia. p.bharadwaj@ecu.edu.au.
Tanya Solomon *School of Pharmacy and Biomedical Sciences, Curtin Health and Innovation Research Institute (CHIRI), Faculty of Health Sciences, Curtin University, Bentley, WA, 6107, Australia.ORCID http://orcid.org/0000-0001-7762-9809
Bikash R SahooBiophysics and Department of Chemistry, Biomedical Engineering, Macromolecular Science and Engineering, University of Michigan, Ann Arbor, MI, 48109-1055, USA.
Katarzyna IgnasiakSchool of Molecular Sciences, The University of Western Australia, Crawley, WA, 6009, Australia.ORCID http://orcid.org/0000-0001-7742-4619
Scott GaskinSchool of Pharmacy and Biomedical Sciences, Curtin Health and Innovation Research Institute (CHIRI), Faculty of Health Sciences, Curtin University, Bentley, WA, 6107, Australia.
Joanne RowlesSchool of Pharmacy and Biomedical Sciences, Curtin Health and Innovation Research Institute (CHIRI), Faculty of Health Sciences, Curtin University, Bentley, WA, 6107, Australia.
Giuseppe VerdileSchool of Pharmacy and Biomedical Sciences, Curtin Health and Innovation Research Institute (CHIRI), Faculty of Health Sciences, Curtin University, Bentley, WA, 6107, Australia.
Mark J HowardCentre for Microscopy, Characterisation and Analysis, The University of Western Australia, Crawley, WA, 6009, Australia.ORCID http://orcid.org/0000-0002-0762-2887
Charles S BondSchool of Molecular Sciences, The University of Western Australia, Crawley, WA, 6009, Australia.ORCID http://orcid.org/0000-0002-9584-6783
Ayyalusamy RamamoorthyBiophysics and Department of Chemistry, Biomedical Engineering, Macromolecular Science and Engineering, University of Michigan, Ann Arbor, MI, 48109-1055, USA.
Ralph N MartinsCentre of Excellence for Alzheimer's disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, 6027, Australia.
Philip NewsholmeSchool of Pharmacy and Biomedical Sciences, Curtin Health and Innovation Research Institute (CHIRI), Faculty of Health Sciences, Curtin University, Bentley, WA, 6107, Australia.
Curtin University · AUEdith Cowan University · AUThe University of Western Australia · AUUniversity of Michigan · USUniversity of Leeds · GB

Funding

Membrane interaction and disruption by the Alzheimer's amyloid-beta peptideR01AG048934 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RAMAMOORTHY, AYYALUSAMY · 2016 to 2020
$2.0M
NIA NIH HHS R01 AG048934
6 · The paper itself

Abstract

Human pancreatic islet amyloid polypeptide (hIAPP) and beta amyloid (Aβ) can accumulate in Type 2 diabetes (T2D) and Alzheimer's disease (AD) brains and evidence suggests that interaction between the two amyloidogenic proteins can lead to the formation of heterocomplex aggregates. However, the structure and consequences of the formation of these complexes remains to be determined. The main objective of this study was to characterise the different types and morphology of Aβ-hIAPP heterocomplexes and determine if formation of such complexes exacerbate neurotoxicity. We demonstrate that hIAPP promotes Aβ oligomerization and formation of small oligomer and large aggregate heterocomplexes. Co-oligomerized Aβ42-hIAPP mixtures displayed distinct amorphous structures and a 3-fold increase in neuronal cell death as compared to Aβ and hIAPP alone. However, in contrast to hIAPP, non-amyloidogenic rat amylin (rIAPP) reduced oligomer Aβ-mediated neuronal cell death. rIAPP exhibited reductions in Aβ induced neuronal cell death that was independent of its ability to interact with Aβ and form heterocomplexes; suggesting mediation by other pathways. Our findings reveal distinct effects of IAPP peptides in modulating Aβ aggregation and toxicity and provide new insight into the potential pathogenic effects of Aβ-IAPP hetero-oligomerization and development of IAPP based therapies for AD and T2D.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsBrainCell Line, TumorDiabetes Mellitus, Type 2HumansIslet Amyloid PolypeptideMicroscopy, Electron, TransmissionNeuronsNuclear Magnetic Resonance, BiomolecularPancreasPeptide FragmentsProtein AggregatesProtein Aggregation, PathologicalProtein MultimerizationAmyloid beta-Peptidesamyloid beta-protein (1-42)Islet Amyloid PolypeptidePeptide FragmentsProtein Aggregates

Identifiers

PMID32587390
PMCPMC7316712
OpenAlexW3037058757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.